Features
Using cryopreserved prepubertal testis tissues – are we getting warmer?
The rising incidence of childhood cancer coupled with increasing survivorship means there is a growing population of childhood cancer survivors with unmet health needs. In the UK around 1 in 500 children and young people are survivors of childhood cancer....
Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...
The Re-humanising Revolution: Breaking the conspiracy of silence
Over the last few years, the mental and emotional wellbeing of those who work in medicine has come under scrutiny. The author introduces a new resource. Working in healthcare has always been stressful but never more so than today. In...
Intravesical GAG replacement therapies for bladder pain syndrome / interstitial cystitis – an update
The barrier function of the glycosaminoglycan (GAG) layer of the urothelium was identified by Parsons in 1975, and intravesical therapies to treat chronic inflammatory conditions of the bladder were developed soon after. However, the active role of the urothelium in...
Immunotherapy in renal cancer
Renal cell carcinoma (RCC) is the sixth most common solid organ cancer in the UK. In 2018, there were 403,262 people diagnosed worldwide with the disease (2.2% of all cancer cases), and it accounted for 175,098 deaths in total (1.8%...
Urinary biomarkers for surveillance of non-muscle invasive bladder cancer
Bladder cancer (BC) is the ninth most common cancer worldwide with a yearly incidence of approximately 430,000 cases. There is a male predominance and it is the seventh most common cancer in men worldwide [1]. Non-muscle invasive bladder cancer (NMIBC)...
Getting it Right First Time in urology: the implementation phase
The Getting it Right First Time (GIRFT) programme is the largest and most comprehensive initiative to improve the quality and efficiency of individual clinical services that the NHS has ever instigated. The programme falls under the auspices of NHS Improvement...
History of prostate biopsy – part 2
For Part 1 of this topic is available here. The major limitations of the transrectal ultrasound (TRUS) guided prostate biopsy (PBx) protocols are the risk of profound sepsis and the risk of persistently significant false negative rates, related to the...
Biomarkers in prostate cancer detection
Prostate cancer (PCa) is the second most common cancer in men with an estimated prevalence of 1.1 million worldwide in 2012. This heterogeneous disease resulted in approximately 307,000 deaths, making it the fifth leading cause of cancer-related death in men...
Training to be a urologist: how risky is it?
The NHS and urology face challenging times in trying to provide quality patient care efficiently and economically. Urology trainees are experiencing conflicting pressures with a new contract, a challenging on-call system and changing training requirements in an overstretched, centralised service...
History of prostate biopsy – part 1
Part 2 of this topic is available here. Prostate biopsy (PBx) to exclude cancer has been part of clinical practice since the beginning of the 20th Century. PBx techniques have evolved over time to optimally address some of the unique...
Simulation-based training of procedural skills: application and integration of educational theories
Educational theories: how familiar are we with these theories and their application in our training? As a Simulation Fellow I have been involved in teaching specific procedural skills and running full immersion simulation sessions. This experience has exposed me to...
